TITLE

Commission approves UCB purchase of Schwarz Pharma

AUTHOR(S)
Gibson, Jane
PUB. DATE
November 2006
SOURCE
ICIS Chemical Business;11/27/2006, Vol. 1 Issue 45, p11
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports that the European Commission has approved the proposed acquisition deal between Germany's Schwarz Pharma and Belgian biopharmaceuticals and chemicals company UCB. The deal, which is valued at €4.4 billion, was announced in September 2006, and will not significantly impede effective competition in the European Economic Area. According to the commission, the two firms' activities overlap in a number of over-the-counter and prescription medicines.
ACCESSION #
23413119

 

Related Articles

  • UCB: continuing the European Mid-Pharma consolidation craze.  // PharmaWatch: CNS;Nov2006, Vol. 5 Issue 11, p4 

    The article reports that an offer of E4.4 billion has been made by UCB SA for Schwarz Pharma AG, a pharmaceutical company. The new company is expected to specialize in neurology along with the therapeutic areas of oncology and inflammation. Small molecule therapies is one of the specialized...

  • SWOT Analysis.  // Schwarz Pharma AG SWOT Analysis;Jun2007, p5 

    A business analysis of Schwarz Pharma AG, a pharmaceutical company engaged in the development and marketing of drugs for the treatment of central neurology, cardiovascular and gastrointestinal diseases, is provided, focusing on its strengths, weaknesses, opportunities for improvement and threats...

  • SWOT Analysis.  // Schwarz Pharma AG SWOT Analysis;Jan2008, p5 

    A business analysis of Schwarz Pharma AG, which is a pharmaceutical company engaged in the development and marketing of drugs for the treatment of central neurology, cardiovascular and gastro intestinal diseases is provided, focusing on its strengths, weaknesses, opportunities for improvement...

  • UCB/Schwarz: a leading CNS proposition moves a step closer.  // PharmaWatch: CNS;Jan2007, Vol. 6 Issue 1, p4 

    The article focuses on the acquisition of Schwarz Pharma Inc. by UCB Pharma Inc. The acquisition gives UCB the excess of 76% of the share capital of Schwarz Pharma and is expected to create a leading neurology-focused pharmaceuticals group. From an earnings perspective, the acquisition is...

  • UCB/Schwarz: a leading CNS proposition moves a step closer.  // PharmaWatch: Monthly Review;Jan2007, Vol. 6 Issue 1, p18 

    The article presents the author's view regarding the $5.5 billion takeover of Schwarz Pharma AG by UCB Pharma Inc. According to the author, the acquisition allowed UCB to receive tenders in excess of 76 percent of the share capital of Schwarz Pharma. Also, the deal will create a leading...

  • COMPANY SPOTLIGHT - UCB.  // PharmaWatch: Biotechnology;Oct2006, Vol. 5 Issue 10, p21 

    The article presents information about Belgium-based chemical and pharmaceuticals group UCB Group Ltd. It is one of the largest pharmaceutical and chemical businesses in the country. It deals in three different industrial areas, namely pharmaceuticals, chemicals, and films. The company is...

  • Global M&A Heats Up. S. H. // Pharmaceutical Executive;Nov2006, Vol. 26 Issue 11, p31 

    The article reports on the acquisition of several pharmaceutical companies in Europe. The acquired companies includes Serono, Altana Pharma and Schwarz Pharma, which are small, family-controlled companies. Merck KgaA, will become the majority shareholder. Altana, the German company will be...

  • COMPANY SPOTLIGHT - UCB.  // PharmaWatch: Monthly Review;Oct2006, Vol. 5 Issue 10, p48 

    The article offers information on the Belgium-based pharmaceutical and chemical firm UCB Group Ltd. and its business plans. The company is planning to acquire Schwarz Pharma AG to boost its growth potential. It had acquired Great Britain based Celltech in the year 2004. The group focuses on...

  • European News.  // Management Services;May96, Vol. 40 Issue 5, p24 

    This article presents several news items related to directives issued by the European Commission, as of May 1, 1996. The regulatory framework on mergers between companies within the European Union (EU) is fragmented. The Commissions Green Paper addresses an issue which requires up-dating and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics